Tyco to Buy Medical Device Maker Bard for $3.2 Billion
EXETER, N.H. — In another major medical products deal Wednesday, Tyco International Ltd. agreed to buy C.R. Bard Inc. for about $3.2 billion, giving Tyco catheters, hernia-repair devices and other medical items it can team with the surgical balloons and instruments it already sells.
Tyco, the second-biggest maker of health-care supplies behind Johnson & Johnson, will pay $60 in stock for each share of Bard--a 30% premium to Bard’s share price Tuesday.
The news sent Bard’s shares soaring $10.09, or 22%, to $56.09 on the New York Stock Exchange. Tyco shares eased 70 cents to $56.30, also on the NYSE.
Medical supplies made up $6.47 billion of conglomerate Tyco’s $28.9 billion in sales last year. Tyco also owns such medical brands as Kendall and U.S. Surgical.
Bard, based in Murray Hill, N.J., had sales last year of $1.1 billion.
The deal will add about 5 cents a share to Tyco’s profit in the first year, Chief Executive Dennis Kozlowski said.
Most of Bard’s sales are to U.S. firms and hospitals. By comparison, about 35% of Tyco’s medical sales are foreign. Tyco said it expects to boost Bard’s foreign sales.
Tyco won’t reduce Bard’s research budget, but it will cut about $235 million in other costs.
Bard already had planned to shut 12 of 21 manufacturing sites, Kozlowski said. In January, Bard said plant closings over three years would save $40 million to $60 million before taxes annually.
“Bard was ready to undertake some massive changes in consolidation of facilities,” Kozlowski said. “I think the board felt it was a good time to consider a sale.”
“Bard is the kind of quality asset that Tyco shareholders are going to like since it doesn’t have the need for a major make-over,” said John Hayes, an analyst at Independence Investment Associates, which owns Tyco shares.
Tyco also is the biggest maker of electronic connectors, undersea fiber-optic cable and security and fire prevention systems.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.